{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:17:39Z","timestamp":1789690659803,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jval.2021.09.005","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T04:42:11Z","timestamp":1635309731000},"page":"435-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort"],"prefix":"10.1016","volume":"25","author":[{"given":"Mi Jun","family":"Keng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Mafham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislava","family":"Mihaylova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2021.09.005_bib1","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"9","key":"10.1016\/j.jval.2021.09.005_bib2","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/diacare.27.9.2262","article-title":"Guidelines for computer modeling of diabetes and its complications","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jval.2021.09.005_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs","volume":"29","author":"Hex","year":"2012","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.jval.2021.09.005_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/dc12-2625","article-title":"Economic costs of diabetes in the U.S. in 2012","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jval.2021.09.005_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/dme.12647","article-title":"The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)","volume":"32","author":"Alva","year":"2015","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.jval.2021.09.005_bib7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2021.09.005_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-130-6-199903160-00016","article-title":"Assessing the generalizability of prognostic information","volume":"130","author":"Justice","year":"1999","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jval.2021.09.005_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/heartjnl-2011-301247","article-title":"Risk prediction models: II. External validation, model updating, and impact assessment","volume":"98","author":"Moons","year":"2012","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.jval.2021.09.005_bib10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A\u00a0model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.jval.2021.09.005_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.jval.2021.09.005_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","article-title":"Validation of the IMS CORE diabetes model","volume":"17","author":"McEwan","year":"2014","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2021.09.005_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110235","article-title":"Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations","volume":"9","author":"Lundqvist","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jval.2021.09.005_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40273-016-0471-3","article-title":"Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)","volume":"35","author":"Willis","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2021.09.005_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12962-015-0038-8","article-title":"Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model","volume":"13","author":"McEwan","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"10.1016\/j.jval.2021.09.005_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2337\/dc12-1120","article-title":"Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data","volume":"36","author":"Leal","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jval.2021.09.005_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2337\/dc17-2002","article-title":"Validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from diverse longitudinal cohorts in the U.S","volume":"41","author":"Basu","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.jval.2021.09.005_bib18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","article-title":"Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials","volume":"5","author":"Basu","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.jval.2021.09.005_bib19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40273-019-00822-4","article-title":"Performance of the UKPDS Outcomes Model 2 for predicting death and cardiovascular events in patients with type 2 diabetes mellitus from a German population-based cohort","volume":"37","author":"Laxy","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2021.09.005_bib20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/dom.14311","article-title":"Prediction of mortality and major cardiovascular complications in type 2 diabetes: external validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts","volume":"23","author":"Pagano","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.jval.2021.09.005_bib21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jval.2020.04.1832","article-title":"Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the ninth Mount Hood diabetes challenge","volume":"23","author":"Si","year":"2020","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2021.09.005_bib22","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00125-013-2933-x","article-title":"Prediction of mortality and macrovascular complications in type 2 diabetes: validation of the UKPDS Outcomes Model in the Casale Monferrato Survey, Italy","volume":"56","author":"Pagano","year":"2013","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.jval.2021.09.005_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2021.09.005_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40273-014-0225-z","article-title":"Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK","volume":"33","author":"McEwan","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2021.09.005_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2017.12.006","article-title":"ASCEND: A Study of Cardiovascular Events iN Diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes","volume":"198","author":"Bowman","year":"2018","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.jval.2021.09.005_bib26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jval.2021.09.005_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jval.2021.09.005_bib28","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jval.2021.09.005_bib29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jval.2021.09.005_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14656","article-title":"Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)","volume":"38","author":"Leal","year":"2021","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.jval.2021.09.005_bib31","first-page":"54","article-title":"Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy","volume":"1","author":"Efron","year":"1986","journal-title":"Statist Sci"},{"issue":"1","key":"10.1016\/j.jval.2021.09.005_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"issue":"10","key":"10.1016\/j.jval.2021.09.005_bib33","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jval.2021.09.005_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement [published correction appears in Ann Intern Med. 2015;162(8):600]","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.jval.2021.09.005_bib36","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/heartjnl-2016-309573","article-title":"Trends in the epidemiology of cardiovascular disease in the UK","volume":"102","author":"Bhatnagar","year":"2016","journal-title":"Heart"},{"issue":"9131","key":"10.1016\/j.jval.2021.09.005_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jval.2021.09.005_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00125-018-4796-7","article-title":"Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015","volume":"62","author":"Read","year":"2019","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.jval.2021.09.005_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2213-8587(16)30010-9","article-title":"The changing face of diabetes complications","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jval.2021.09.005_bib40","doi-asserted-by":"crossref","first-page":"d8059","DOI":"10.1136\/bmj.d8059","article-title":"Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study [published correction appears in BMJ. 2013;347:f7379]","volume":"344","author":"Smolina","year":"2012","journal-title":"BMJ"},{"issue":"10120","key":"10.1016\/j.jval.2021.09.005_bib41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jval.2021.09.005_bib42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.CIR.0000118498.35499.B2","article-title":"Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000","volume":"109","author":"Unal","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jval.2021.09.005_bib43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/CIRCULATIONAHA.107.705947","article-title":"How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study","volume":"117","author":"Hardoon","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jval.2021.09.005_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1146\/annurev-publhealth-031210-101211","article-title":"Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care","volume":"32","author":"Ford","year":"2011","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.jval.2021.09.005_bib45","doi-asserted-by":"crossref","first-page":"g1088","DOI":"10.1136\/bmj.g1088","article-title":"Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data","volume":"348","author":"Hotchkiss","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jval.2021.09.005_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00125-017-4519-5","article-title":"Rates of glycaemic deterioration in a real-world population with type 2 diabetes","volume":"61","author":"Donnelly","year":"2018","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.jval.2021.09.005_bib47","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/CIRCULATIONAHA.118.037885","article-title":"Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks","volume":"139","author":"Sattar","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jval.2021.09.005_bib48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/BF00400195","article-title":"UK prospective diabetes study (UKPDS). VIII. Study design, progress and performance","volume":"34","year":"1991","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.jval.2021.09.005_bib49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","article-title":"Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting","volume":"16","author":"Palmer","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2021.09.005_bib50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-006-0561-4","article-title":"Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"50","author":"Raikou","year":"2007","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.jval.2021.09.005_bib51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dom.14268","article-title":"Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States","volume":"23","author":"Reifsnider","year":"2021","journal-title":"Diabetes Obes Metab"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521017447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521017447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:26:50Z","timestamp":1761096410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521017447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1098301521017447"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.09.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}